Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization

E-ISSN： 1875-5453|15|2|218-232

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.15, Iss.2, 2014-02, pp. : 218-232

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype

By Al-Shurbaji Ayman Säwe Juliette

European Journal of Clinical Pharmacology, Vol. 57, Iss. 12, 2002-02 ,pp. : 877-881

Springer Publishing Company

Access to resources Recommend Favorite

CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene

By Skierka Jennifer M Walker Denise L Peterson Sandra E O’Kane Dennis J Black John Logan

Pharmacogenomics, Vol. 13, Iss. 8, 2012-06 ,pp. : 951-954

Future Medicine

Access to resources Recommend Favorite

Prediction of In Vivo Drug-Drug Interactions from In Vitro Data: Factors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4

By Brown Hayley S. Galetin Aleksandra Hallifax David Houston J. Brian

Clinical Pharmacokinetics, Vol. 45, Iss. 10, 2006-01 ,pp. : 1035-1050

Adis International

Access to resources Recommend Favorite

Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers

By Gassó Patricia Papagianni Katerina Mas Sergi de Bobadilla Ramón Fernández Arnaiz Joan Albert Bernardo Miquel Lafuente Amalia

Pharmacogenomics, Vol. 14, Iss. 13, 2013-10 ,pp. : 1551-1563

Future Medicine

Access to resources Recommend Favorite

Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers

By Peññas-LLedóó Eva M Dorado Pedro Pacheco Rodrigo Gonzáález Idilio LLerena Adriáán

Pharmacogenomics, Vol. 10, Iss. 7, 2009-07 ,pp. : 1111-1120

Future Medicine

Access to resources Recommend Favorite